References
- The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of Non-Hodgkin's Lymphomas. Summary and description of a Working Formulation for clinical usage. Cancer 1982; 9: 2112–2135
- Lennert K., Mohri N. Malignant lymphomas other than Hodgkin's disease. Springer Verlag, New York 1978
- DeVita V. T., Chabner B., Hubbar F. P., et al. Advanced diffuse histiocytic lymphoma: a potential curable disease. Lancet 1973; 1: 248–250
- Coiffier B., Gisselbrecht C., Vose J. M., et al. Prognostic Factors in Aggressive Malignant Lymphomas: Description and Validation of a Prognostic Index That Could Identify Patients Requiring a More Intensive Therapy. J. Clin. Oncol. 1991; 9: 211–219
- Coiffier B., Brousse N., Peuchmaur M., et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. Ann. Oncol. 1990; 1: 45–50
- Coiffier B., Gisselbrecht C., Herbrecht R., et al. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J. Clin. Oncol. 1989; 7: 1018–26
- Shipp M., Harrington D., Anderson J., et al. Development of a predictive model for aggressive lymphoma: the International NHL Prognostic Factors Project. 28th Meeting ASCO. 1992; 1084, Abst
- Dumontet C., Anderson J. R., Sebban C., et al. Elderly non-Hodgkin's lymphoma patients have comparable prognostic factors but a poorer outcome than younger patients. 28th Meeting ASCO. 1992; 1118, Abst
- Vose J. M., Armitage J. O., Wesenburger D. D., et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J. Clin. Oncol. 1988; 6: 1838–1844
- Coiffier B. Prognostic factors in Hodgkin's and non-Hodgkin's lymphomas. Current Opinion Oncol. 1991; 3: 843–851
- Coiffier B., Lepage E. Prognosis of aggressive lymphomas: a study of five prognostic models with patients included in the LNH-84 regimen. Blood 1989; 74: 558–564
- Swan F., Velasquez W. S., Tucker S., et al. A new se-rologic staging system for large-cell lymphomas based on initial B2-macroglobulin and lactate dehydrogenase levels J. Clin. Oncol. 1989; 7: 1518–1527
- Coiffier B., Barbier Y., Bienvenu J., et al. Increased plasma tumor necrosis factor alpha is correlated with adverse prognostic factors and poor response to treatment in non-Hodgkin lymphomas. 28th Meeting ASCO. 1992; 1157, Abst
- Kwak L. W., Halpern J., Olshen R. A., Horning S. J. Prognostic Significance of Actual Dose Intensity in Diffuse Large-Cell Lymphoma: Results of a Tree-Structured Survival Analysis. J. Clin. Oncol. 1990; 8: 963–977
- Armitage J. O., Cheson B. D. Interpretation of clinical trials in diffuse large-cell lymphoma. J. Clin. Oncol. 1988; 6: 1335–1347
- Weeks J. C., Yeap B. Y., Canellos G. P., Shipp M. A. Value of follow-up procedures in patients with large cell lymphoma who achieve a complete remission. J. Clin. Oncol. 1991; 9: 1196–1203
- Schouten H. C., Sanger W. G., Weisenburger D. D., Anderson J., Armitage J. O. Chromosomal Abnormalities in Untreated Patients with Non-Hodgkin's Lymphoma: Associations with Histology, Clinical Characteristics, and Treatment Outcome. Blood 1990; 75: 1841–1847
- Shipp M. A., Harrington D. P., Klatt M. M., et al. Identification of major prognostic subgroups of patients with large cell lymphoma treated with m-BACOD or M-BACOD. Ann. Int. Med. 1986; 104: 757–765
- Jagannath S., Velasquez W. S., Tucker S. L., et al. Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. J. Clin. Oncol. 1986; 4: 859–865